Diabetic Peripheral Neuropathy (DPN)

Also known as: Peripheral Diabetic Neuropathy / Diabetic Peripheral Neuropathy / Diabetic Neuropathy Peripheral / Diabetic neuropathy / Diabetic Neuropathies

DrugDrug NameDrug Description
DB00476DuloxetineDuloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686.[A178741] Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder.[L6454] It has since received approval for a variety of indications including the treatment of neuropathic pain, Generalized Anxiety disorder, osteoarthritis, and stress incontinence. Duloxetine continues to be investigated for the treatment of pain in cancer, surgery, and more.
DrugDrug NamePhaseStatusCount
DB00825Levomenthol1 / 2Recruiting1
DB00742Mannitol1 / 2Recruiting1
DB14933Nicotinamide riboside1 / 2Recruiting1
DB04889Bicifadine2Unknown Status1
DB15229CNV-21979442Completed1
DB05492Epicept NP-12Completed1
DB00996Gabapentin2Completed1
DB00727Nitroglycerin2Completed1
DB00230Pregabalin2Completed2
DB12335Tanezumab2Terminated1
DB06774Capsaicin3Completed1
DB00230Pregabalin3Completed2
DB06204Tapentadol3Completed1
DB00230Pregabalin4Completed2
DB016325-O-phosphono-alpha-D-ribofuranosyl diphosphateNot AvailableCompleted1
DB01276ExenatideNot AvailableCompleted1
DB00047Insulin glargineNot AvailableCompleted1
DB03614MethylcobalaminNot AvailableNot Yet Recruiting1